University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor

Matthew R. Cooperberg, M.D.

Urologic cancer specialist

Dr. Matthew Cooperberg is a urologic cancer expert at the UCSF Helen Diller Family Comprehensive Cancer Center. He specializes in the diagnosis and management of genitourinary malignancy, and using minimally invasive techniques to treat benign and malignant diseases. Cooperberg, who is interested in new technologies, performs robotic, laparoscopic, endoscopic and percutaneous surgeries. He developed a new prostate cancer risk assessment tool called the Cancer of the Prostate Risk Assessment (UCSF-CAPRA) score.

Cooperberg earned a medical degree and master's of public health at Yale University. He then completed training in general surgery and urology at UCSF, followed by a urologic oncology fellowship under the guidance of Dr. Peter Carroll. Cooperberg is a candidate member of the American Urological Association (AUA), Western Section of the AUA and the American College of Surgeons. He has written over 50 peer-reviewed scientific articles, nine chapters and has lectured nationally and internationally about malignant and benign urologic disease, with a particular focus on prostate cancer.

Clinics

Prostate Cancer Center
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Prostate Cancer Risk and Prevention Clinic
1600 Divisadero St, Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Urologic Surgery and Oncology
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

More about Matthew R. Cooperberg

Additional Languages

Spanish

Education

Yale University School of Medicine 2000

Residencies

UCSF Medical Center, Urology 2008

Selected Research and Publications

  1. Cooperberg MR. Thwarting High-risk Prostate Cancer: The Right Treatments for the Right Patients. Eur Urol. 2012 Jun; 61(6):1107-9.
  2. Aaronson DS, Odisho AY, Hills N, Cress R, Carroll PR, Dudley RA, Cooperberg MR. Proton beam therapy and treatment for localized prostate cancer: if you build it, they will come. Arch Intern Med. 2012 Feb 13; 172(3):280-3.
  3. Akaza H, Carroll P, Cooperberg MR, Hinotsu S. Fifth Joint Meeting of J-CaP and CaPSURE: Advancing the Global Understanding of Prostate Cancer and Its Management. Jpn J Clin Oncol. 2012 Mar; 42(3):226-36.
  4. Cooperberg MR, Odisho AY, Carroll PR. Outcomes for radical prostatectomy: is it the singer, the song, or both? J Clin Oncol. 2012 Feb 10; 30(5):476-8.
  5. Cooperberg MR. Adverse effects of androgen deprivation and the limits of national tumor registries. Eur Urol. 2012 Apr; 61(4):701-3.
  6. Cooperberg MR. High-risk prostate cancer: treat the prostate. Lancet. 2012 Dec 17; 378(9809):2056-7.
  7. Wu AK, Reese AC, Cooperberg MR, Sadetsky N, Shinohara K. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):100-5.
  8. Cooperberg MR. External-beam radiation therapy should be given with androgen deprivation treatment for intermediate-risk prostate cancer: new confirmatory evidence. Asian J Androl. 2012 Jan; 14(1):132-3.
  9. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR. Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores? BJU Int. 2012 May; 109(10):1520-4.
  10. Cooperberg MR. Words of wisdom. Re: Radical prostatectomy versus watchful waiting in early prostate cancer. Eur Urol. 2011 Oct; 60(4):868-9.
  11. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011 Sep 21; 306(11):1205-14.
  12. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR. Androgen deprivation therapy and cardiovascular risk. J Clin Oncol. 2011 Sep 10; 29(26):3510-6.
  13. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol. 2011 Sep 20; 29(27):3669-76.
  14. Cooperberg MR, Mallin K, Kane CJ, Carroll PR. Treatment trends for stage I renal cell carcinoma. J Urol. 2011 Aug; 186(2):394-9.
  15. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011 Nov 15; 117(22):5039-46.
  16. Cooperberg MR. Editorial comment. Urology. 2011 Jun; 77(6):1336-7.
  17. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol. 2011 Jul 10; 29(20):2795-800.
  18. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol. 2011 May; 185(5):1656-60.
  19. Sadetsky N, Greene K, Cooperberg MR, Hubbard A, Carroll PR, Satariano W. Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. Cancer. 2011 Oct 1; 117(19):4406-13.
  20. Porten SP, Cooperberg MR, Konety BR, Carroll PR. The example of CaPSURE: lessons learned from a national disease registry. World J Urol. 2011 Jun; 29(3):265-71.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.